← Leaderboards
Jonas Bernard Galper
Brigham And Women'S Hospital
$11,534,469
Attributed
$11,534,469
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$11,534,469 · 6
By mechanism
R01$11,097,219 · 5
R21$437,250 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Arrhythmia”
- Dan M Roden · Vanderbilt University Medical Center$63,173,998
- Lynn A Sleeper · New England Research Institutes, Inc.$48,939,627
- Donald M Bers · Cincinnati Childrens Hosp Med Ctr$40,886,752
- Russell E Ware · Duke University$30,715,534
- David Herlie Robertson · Vanderbilt University$28,928,663
- Henry R Halperin · Johns Hopkins University$27,245,374
Research focus
ArrhythmiaCholesterolDiabetes MellitusResponseMuscle CellsHeartDiabeticSignal TransductionFunctional DisorderLaboratory MouseInsulinGene ExpressionPlayDiabetic PatientSudden DeathAdenylate CyclaseMyocardial InfarctionCardiogenesisGuanine Nucleotide Binding ProteinIncidenceBinding (Molecular Function)AcetylcholineLifePredisposition
Grant awards (29)
A Role of PKG1a and Inhibitors of cGMP Phosphodiesterase in Post MI VT in Mouse Models for Type II Diabetes and Metabolic Syndrome$647,562
R01 · FY2023 · HL · contact PI
A Role of PKG1a and Inhibitors of cGMP Phosphodiesterase in Post MI VT in Mouse Models for Type II Diabetes and Metabolic Syndrome$674,332
R01 · FY2022 · HL · contact PI
A Role of PKG1a and Inhibitors of cGMP Phosphodiesterase in Post MI VT in Mouse Models for Type II Diabetes and Metabolic Syndrome$674,332
R01 · FY2021 · HL · contact PI
A Role of PKG1a and Inhibitors of cGMP Phosphodiesterase in Post MI VT in Mouse Models for Type II Diabetes and Metabolic Syndrome$663,296
R01 · FY2020 · HL · contact PI
Role of Sterols and Insulin in Cardiac Autonomic Response$374,636
R01 · FY2013 · HL · contact PI
Role of Sterols and Insulin in Cardiac Autonomic Response$393,525
R01 · FY2012 · HL · contact PI
Role of Sterols and Insulin in Cardiac Autonomic Response$397,500
R01 · FY2011 · HL · contact PI
An Animal Model of Diabetic Autonomic Neuropathy: Study of Mechanism and Therapy$583,678
R01 · FY2010 · HL · contact PI
Role of Sterols and Insulin in Cardiac Autonomic Response$397,500
R01 · FY2010 · HL · contact PI
Gender Specific Complications of Diabetic Autonomic Neuropathy: A New Mouse Model$198,750
R21 · FY2010 · HL · contact PI
An Animal Model of Diabetic Autonomic Neuropathy: Study of Mechanism and Therapy$579,605
R01 · FY2009 · HL · contact PI
Gender Specific Complications of Diabetic Autonomic Neuropathy: A New Mouse Model$238,500
R21 · FY2009 · HL · contact PI
An Animal Model of Diabetic Autonomic Neuropathy: Study of Mechanism and Therapy$564,084
R01 · FY2008 · HL · contact PI
An Animal Model of Diabetic Autonomic Neuropathy: Study of Mechanism and Therapy$543,139
R01 · FY2007 · HL · contact PI
Role of Sterols & Insulin in Cardiac Autonomic Response$386,383
R01 · FY2007 · HL · contact PI
Role of Sterols & Insulin in Cardiac Autonomic Response$397,924
R01 · FY2006 · HL · contact PI
Role of Sterols &Insulin in Cardiac Autonomic Response$407,500
R01 · FY2005 · HL
Cholesterol Metabolism and Angiogenesis: Role of Statins$405,000
R01 · FY2005 · HL
Role of Sterols &Insulin in Cardiac Autonomic Response$407,083
R01 · FY2004 · HL
Cholesterol Metabolism and Angiogenesis: Role of Statins$405,000
R01 · FY2004 · HL
Cholesterol Metabolism and Angiogenesis: Role of Statins$405,000
R01 · FY2003 · HL
LIPOPROTEIN CONTROL OF RAS &RECEPTOR/EFFECTOR COUPLING$427,139
R01 · FY2002 · HL
Cholesterol Metabolism and Angiogenesis: Role of Statins$241,109
R01 · FY2002 · HL
Cholesterol Metabolism and Angiogenesis: Role of Statins$185,453
R01 · FY2002 · HL
LIPOPROTEIN CONTROL OF RAS &RECEPTOR/EFFECTOR COUPLING$35,832
R01 · FY2002 · HL
LIPOPROTEIN CONTROL OF RAS &RECEPTOR/EFFECTOR COUPLING$395,471
R01 · FY2001 · HL
LIPOPROTEIN CONTROL OF RAS &RECEPTOR/EFFECTOR COUPLING$31,668
R01 · FY2001 · HL
LIPOPROTEIN CONTROL OF RAS &RECEPTOR/EFFECTOR COUPLING$446,856
R01 · FY2000 · HL
LIPOPROTEIN CONTROL OF RAS &RECEPTOR/EFFECTOR COUPLING$26,612
R01 · FY2000 · HL